SCHEMBL3483951

SCHEMBL3483951

O=C(C=Cc1cccc(O)c1)c1ccc(NS(=O)(=O)c2ccc(O)cc2)cc1

nearest known ligand 0.77

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
P4HB P07237 7/20 0.69
LMNA P02545 3/20 0.67
NPSR1 Q6W5P4 3/20 0.67
SMN1; SMN2 Q16637 2/20 0.67
MEN1 O00255 2/20 0.60
MAPT P10636 2/20 0.60
KMT2A Q03164 2/20 0.60
KDM4E B2RXH2 1/20 0.60
ALDH1A1 P00352 1/20 0.60
GAA P10253 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3483949 1.00 P4HB (0.69) P4HBLMNANPSR1SMN1; SMN2MEN1
SCHEMBL30384818 1.00 P4HB (0.69) P4HBLMNANPSR1SMN1; SMN2MEN1
SCHEMBL25278797 0.93 P4HB (0.69) P4HBLMNANPSR1SMN1; SMN2MEN1
SCHEMBL31233323 0.93 P4HB (0.69) P4HBLMNANPSR1SMN1; SMN2MEN1
SCHEMBL25195571 0.93 P4HB (0.69) P4HBLMNANPSR1SMN1; SMN2MEN1
SCHEMBL3483850 0.92 LMNA (0.79) P4HBLMNANPSR1SMN1; SMN2MEN1
SCHEMBL3483848 0.92 LMNA (0.79) P4HBLMNANPSR1SMN1; SMN2MEN1
SCHEMBL3484454 0.92 P4HB (0.71) P4HBLMNANPSR1SMN1; SMN2MEN1
SCHEMBL30383444 0.92 P4HB (0.71) P4HBLMNANPSR1SMN1; SMN2MEN1
SCHEMBL3484452 0.92 P4HB (0.71) P4HBLMNANPSR1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2601943-B1 Anti-cancer composition containing chalcone compounds SEOUL NAT UNIV IND FOUNDATION (KR) 2015-07-22 EP claimed
US-20130178533-A1 COMPOSITION FOR DIAGNOSING, TREATING, AND PREVENTING LIVER DISEASE SNU R&DB FOUNDATION (KR) 2013-07-11 US claimed
EP-2601943-A1 Anti-cancer composition containing chalcone compounds Seoul National University Industry Foundation (KR) 2013-06-12 EP claimed
US-20100068730-A1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) 2010-03-18 US claimed
EP-2099440-A1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS Seoul National University Industry Foundation (KR) 2009-09-16 EP claimed
WO-2008069608-A1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS SEOUL NATIONALUNIVERSITY INDUSTRY FOUNDATION (KR) 2008-06-12 WO claimed
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed
EP-2601943-B1 Anti-cancer composition containing chalcone compounds SEOUL NAT UNIV IND FOUNDATION (KR) 2015-07-22 EP disclosed
US-9072698-B2 Method for screening anti-cancer compounds inhibiting function of TM4SF5 and anti-cancer composition containing chalcone compounds SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) 2015-07-07 US disclosed
US-9057725-B2 Composition for diagnosing, treating, and preventing liver disease SNU R&DB FOUNDATION (KR) 2015-06-16 US disclosed
US-20130178533-A1 COMPOSITION FOR DIAGNOSING, TREATING, AND PREVENTING LIVER DISEASE SNU R&DB FOUNDATION (KR) 2013-07-11 US disclosed
EP-2601943-A1 Anti-cancer composition containing chalcone compounds Seoul National University Industry Foundation (KR) 2013-06-12 EP disclosed
US-8445722-B2 Method for screening anti-cancer compounds inhibiting function of TM4SF5 and anti-cancer composition containing chalcone compounds INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY (KR) 2013-05-21 US disclosed
EP-2099440-B1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 SEOUL NAT UNIV IND FOUNDATION (KR) 2013-02-27 EP disclosed
US-20120282619-A1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY 2012-11-08 US disclosed
US-20100068730-A1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B P4HB 552/4885LMNA 1180/4885NPSR1 4347/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 P4HB 469/4885LMNA 1817/4885NPSR1 4282/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 P4HB 469/4885LMNA 1817/4885NPSR1 4282/4885
US-20100068730-A1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS TM9SF4, TM9SF2, TM9SF3 P4HB 1301/4885LMNA 1874/4885NPSR1 4804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.